Cell-Based Cerebral Palsy Trials Review Evaluates 1,087 Children Across 18 Studies
A systematic review published following a July 2025 literature search has gathered 18 clinical studies evaluating cell-based and related regenerative treatments in 1,087 children with cerebral palsy. Conducted by researchers at Jazan University in Saudi Arabia alongside co-authors from other Saudi and Sudanese institutions, the paper examines randomized trials, open-label projects, retrospective analyses, and uncontrolled studies published between January 2010 and January 2025.
Rather than pooling the data into a single statistical meta-analysis, the authors chose to describe the findings study by study. They determined that the trials varied too widely in study design, cell product composition, dosage, outcome measures, and follow-up duration to combine meaningfully. The review’s protocol was registered on PROSPERO under the identifier CRD420251083077 and followed the PRISMA checklist, drawing on searches across PubMed, Web of Science, the Cochrane Library, and ScienceDirect.
Umbilical Cord Products and Motor Function Gains in Clinical Trials
The review found that umbilical cord-derived products accounted for 73.5% of the total patient population, representing 799 of the 1,087 children analyzed across the 13 studies utilizing these materials. Bone marrow-derived products were administered to 20.3% of the participants, or 221 children across four studies. Granulocyte colony-stimulating factor (G-CSF) accounted for 4.3% of children in one trial, while a mixed product group comprised the remaining 1.8%.
The authors reported that umbilical cord-derived treatments—particularly cord blood administered alongside erythropoietin (EPO)—produced the clearest motor function gains. Interventions utilizing bone marrow-derived cells yielded more modest and variable results. Intravenous delivery was utilized across 10 studies, while intrathecal delivery appeared in six studies, with varying protocols providing either single doses or repeated administrations ranging from weekly to monthly intervals.
Safety Profiles and Transient Adverse Events in Regenerative Protocols
Safety data recorded across nearly all 18 studies indicated that adverse events were predominantly mild and short-lived. Common side effects included transient fever, headache, gastrointestinal upset, mild respiratory infections, back pain, and temporary discomfort following intrathecal injections. The authors noted that intrathecal delivery protocols triggered a higher frequency of procedure-related events, such as headaches and back pain, compared to intravenous administration routes.
Serious adverse events were rare. Isolated reports included a seizure exacerbation in a Polish study where a child required a medication adjustment for worsened epilepsy, and a single death in a Korean cord blood trial that investigators attributed to causes unrelated to the treatment. The review documented no instances of treatment-related cancers, transplant reactions, or ectopic tissue formation during the available follow-up windows, which remained predominantly short-term.
Experimental Status and Current Methodological Limitations
The review concludes that while regenerative medicine therapies show promising functional improvements and reassuring short-term safety profiles, they must still be regarded strictly as experimental treatments. The authors emphasize that these interventions should be confined to well-designed clinical trials, do not support routine clinical use, and must serve only as a complement to traditional rehabilitation rather than a replacement.
Significant limitations constrained the review’s conclusions. The exclusion of studies that lacked open-access status removed 12 of the 21 full-text exclusions, meaning selection depended partly on publishing models rather than research quality. Furthermore, the absence of a meta-analysis left overall effect sizes uncalculated, and the inclusion of open-label and uncontrolled designs introduced risks of bias related to rehabilitation, caregiver involvement, and regression to the mean.
Frequently Asked Questions About Cerebral Palsy Stem Cell Research
Which specific cell products were most frequently studied for cerebral palsy in this review?
Umbilical cord-derived products dominated the literature, representing 73.5% of the children studied. These included allogeneic or autologous umbilical cord blood given alone or with erythropoietin, umbilical cord mesenchymal stem cells, and Wharton’s jelly MSCs administered via intravenous or intrathecal routes.
What databases and search parameters were utilized for this systematic review?
Researchers searched PubMed, Web of Science, the Cochrane Library, and ScienceDirect in July 2025. The literature search captured English-language studies published between January 2010 and January 2025 that involved at least three children with cerebral palsy.
How do the researchers view the mechanisms of these cell-based therapies?
The authors suggest that these protocols function primarily through overlapping mechanisms involving modulation of inflammation, neuroprotection, and support for axonal growth and synaptic plasticity, rather than achieving a true structural replacement of lost brain cells.
Keep reading